Free Trial

Reneo Pharmaceuticals Q1 2023 Earnings Report

Reneo Pharmaceuticals EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Reneo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reneo Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

Reneo Pharmaceuticals Earnings Headlines

Onkure Therapeutics Inc (OKUR)
Musk’s real agenda in Washington…
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
See More Reneo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reneo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reneo Pharmaceuticals and other key companies, straight to your email.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals (NASDAQ:RPHM), a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

View Reneo Pharmaceuticals Profile

More Earnings Resources from MarketBeat